Greenwich LifeSciences (NASDAQ:GLSI) Receives Buy Rating from HC Wainwright

Greenwich LifeSciences (NASDAQ:GLSI)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They presently have a $36.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 165.88% from the company’s current price.

Greenwich LifeSciences Trading Up 3.5 %

Shares of GLSI opened at $13.54 on Wednesday. Greenwich LifeSciences has a twelve month low of $7.58 and a twelve month high of $21.44. The firm has a market capitalization of $174.40 million, a P/E ratio of -18.81 and a beta of 1.55. The firm’s 50-day moving average is $15.53 and its two-hundred day moving average is $12.51.

Greenwich LifeSciences (NASDAQ:GLSI) last released its quarterly earnings results on Monday, April 15th. The company reported ($0.21) earnings per share for the quarter. Analysts predict that Greenwich LifeSciences will post -0.76 EPS for the current year.

Insider Buying and Selling

In other Greenwich LifeSciences news, CEO Snehal Patel purchased 4,100 shares of the stock in a transaction dated Monday, March 4th. The shares were acquired at an average cost of $13.03 per share, for a total transaction of $53,423.00. Following the completion of the transaction, the chief executive officer now directly owns 5,340,277 shares of the company’s stock, valued at $69,583,809.31. The purchase was disclosed in a filing with the SEC, which is available at this link. Insiders have acquired 11,100 shares of company stock worth $187,133 in the last three months. Corporate insiders own 52.86% of the company’s stock.

Institutional Trading of Greenwich LifeSciences

An institutional investor recently raised its position in Greenwich LifeSciences stock. Vanguard Group Inc. boosted its holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 0.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 223,102 shares of the company’s stock after buying an additional 1,420 shares during the period. Vanguard Group Inc. owned 1.73% of Greenwich LifeSciences worth $4,449,000 at the end of the most recent reporting period. 4.16% of the stock is currently owned by institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.